Payment Rules, Not Algorithms, Are Slowing Health AI Adoption
Artificial intelligence is advancing quickly in medicine, yet routine clinical use remains strikingly limited. The gap is not explained by a lack of models, data, or clinical demand. It is being widened by reimbursement systems that were built for older forms of care and have not kept pace with software-driven tools that change how work is done inside a clinic, hospital, or radiology suite.
The central problem is straightforward: even when an AI product meets regulatory standards and demonstrates clinical usefulness, adoption can stall if payment pathways are unclear, fragmented, or economically unattractive. Health systems do not purchase and deploy new tools in a vacuum. They respond to billing rules, labor costs, integration expenses, and the financial incentives of multiple stakeholders who may not all benefit from the same technology in the same way. In practice, that means a tool can clear one hurdle and still fail at the point where it must be implemented at scale.
A major barrier sits inside the current reimbursement structure itself. Existing payment models were designed around discrete clinician services and procedural acts, not around software that can reduce workload, accelerate triage, or support decision-making across an entire care pathway. When a digital product creates value by saving time rather than by generating a billable service, the economic signal is weak. Clinicians may see the utility immediately; finance departments often do not.
This mismatch has direct bedside consequences. Delayed deployment means slower access to tools that could shorten wait times, reduce documentation burden, or help clinicians manage growing patient volumes. In settings already strained by labor shortages and rising administrative load, an AI system that trims a few minutes from each encounter or helps prioritize urgent cases can have real operational value. Yet if payment frameworks do not recognize that value, the technology can remain trapped in pilot programs and controlled demonstrations.
The article focuses first on AI tools that already fit within existing regulatory pathways. Those products are not blocked by safety or efficacy concerns so much as by the mechanics of payment. One of the clearest examples is the adoption bottleneck around Current Procedural Terminology codes. Without a workable coding route, reimbursement becomes difficult to secure, coverage remains uncertain, and providers have little incentive to take on the cost of implementation. Even when clinical justification is strong, the absence of a stable billing mechanism can keep a tool out of standard practice.
Integration overhead creates another drag on adoption. Installing AI into clinical workflows is rarely as simple as licensing software. Systems must connect to electronic health records, information must move safely and reliably, clinicians must be trained, and technical support must be maintained. Those tasks carry real expense. If pricing models do not account for the cost of embedding the tool into day-to-day care, then reimbursement can fall well short of the actual burden borne by the organization.
A deeper problem lies in the way AI value is distributed. One stakeholder may save time, another may absorb implementation costs, and a third may capture the reimbursement. That fractured incentive structure discourages uptake even when the technology improves efficiency overall. Hospitals and clinics are unlikely to invest heavily in tools that lower total system costs if the savings do not flow back to the organization that pays for deployment. Payment policy, in other words, determines whether clinical efficiency is rewarded or ignored.
The policy response proposed in the article is correspondingly practical. Payment systems need to recognize the cost structure of AI, not force software into reimbursement categories designed for earlier technologies. That means addressing coding bottlenecks, reducing friction around adoption, and aligning pricing with the actual expenses of implementation and use. When a tool requires substantial integration work, reimbursement should reflect that reality rather than assume a negligible marginal cost.
Generative AI adds a new layer of urgency. These systems are moving into health care faster than the payment and oversight infrastructure can comfortably adapt. Unlike narrower tools that perform a defined task, generative systems can influence communication, summarization, decision support, and other functions that are harder to measure with traditional regulatory tools. Their rapid spread makes prospective frameworks necessary rather than optional. Without them, the health system risks deploying software whose effects on patients, clinicians, and workflow are not adequately anticipated or monitored.
The biological and operational logic behind the argument is simple, even if the policy mechanics are not. If AI can reduce administrative strain, improve triage, and help clinicians move faster without sacrificing quality, then payment models should encourage those benefits instead of standing in the way. If reimbursement remains tied to outdated assumptions about how care is delivered, adoption will remain uneven regardless of how capable the algorithms become.
Support for the article came from the National Institutes of Health and the Leukemia and Lymphoma Society. The policy challenge now is whether payment systems can evolve quickly enough to match the pace of health AI before promising tools continue to stall between regulatory clearance and real-world use. The unresolved issue is not whether these systems can work, but whether the economics of care will let them reach patients.